India's Semaglutide Market Set for Generic Boom as Patents Expire, Over 50 Brands Lined Up for Launch, See Full List

A Major GLP-1 Franchise Goes Off Patent

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed by Novo Nordisk under brand names Ozempic (for type-2 diabetes), Wegovy (for chronic weight management), and Rybelsus (the oral formulation for type-2 diabetes), has dominated the obesity and type-2 diabetes market due to its strong clinical results and high patient demand. In India, patents covering semaglutide’s composition and delivery expired or will expire by March 2026, allowing local drugmakers to enter the highly lucrative “anti-obesity/diabetes” space with their own versions.

Also Read: Dr Reddy's Prepares Generic Semaglutide Entry Under Brand Obeda, Targets 60% Price Cut: Report

As per a recent Business Standard report, the recent DCGI clearances for generic semaglutide, including approvals for Sun Pharma’s Noveltreat and Sematrinity, signal the first wave of formal regulatory entries ahead of broader launches.

Prices for the innovators such as Wegovy and Ozempic are high — often above ₹15,000–₹25,000 per month — prompting both price reductions by original manufacturers and intense market interest from generic players.

Also Read: 7 Pharma Firms Eye Generic Semaglutide, Prices May Fall 50% Post Patent Expiry: Report

Why So Many Brands? A Primer on the ‘Slum of Generics’

There are several reasons for the proliferation of branded generics:

1. Patent Expiry Unlocks Competition:

With semaglutide’s exclusivity eroded, any firm with manufacturing and regulatory capability can produce analogues — leading to a free-for-all in brand naming and product positioning.

2. India’s Generics Ecosystem:

India is the “pharmacy of the world,” known for low-cost manufacturing and rapid scale-up of generic APIs and formulations. Multiple players are ready to tap into semaglutide demand for both domestic and export markets.

3. Massive Market Potential:

NDTV reports that Bloomberg analysts estimate the combined obesity and diabetes therapy market could be worth tens of billions globally by the decade’s end; in India alone, semaglutide-class drugs have quickly scaled to hundreds of crores in annual sales.

4. Price Sensitivity and Market Share:

Indian patients are highly price-sensitive, and branded generics with aggressive pricing can rapidly supplant premium innovator therapies, making the segment highly competitive.

Major Semaglutide Generic Brands (India Market Post-Patent)

Brand Name Manufacturer/Marketer

1. Wegovy NovoNordisk

2. Ozempic NovoNordisk

3. Ryblsus NovoNordisk

4. Poviztra emcure

5. Obeda Reddys

6. Mashema Zydus Healthcare

7. Wyntide Corona

8. Semaglip Lloyd

9. Semaglide Alkem

10. Semanat Natco Pharma

11. Semanta Ajanta Pharma

12. Samakind Mankind Pharma

13. Semastar Torrent Pharmaceuticals

14. Semaglut Anthem Biopharma

15. Semaglyn Zydus Healthcare

16. Sematop Ajanta Pharma

17. Semalite Macleods Pharmaceuticals

18. Semaday Macleods Pharma

19. Semathem Themis Medicare Ltd

20. Semapride Micro Labs

21. Semastrike Unison Pharma

22. Semazit Glenmark Pharma

23. Semalup Lupin

24. Zepsema Torrent Pharmaceuticals

25. Semabig Msn Laboratories

26. Semavance Aristo Pharma

27. Trusema Torrent Pharmaceuticals

28. Semaglura Akums Drugs Pharma

29. Semaglu Vida Laboratories Ltd.

30. Semalembic Alembic Pharma

31. Semadirect Aristo Pharma

32. Semaro Alembic Pharma

33. Glusema Cue Labs Pharma

34. Semavic Alkem Laboratories

35. Semaliv Amon Biotech

36. Sematide Blisson Medica

37. Semafit Ajanta Pharma

38. Noveltreat Sun Pharma

39. Sematrinity Sun Pharma

40. Semaryl Intas Pharmaceuticals

41. Zyglutide Hab Pharmaceuticals

42. Semgluta Mankind Pharma

43. Semaglu Mankind Pharma

44. Semglee Mylan Pharmaceuticals

45. Seglu Torrent Pharmaceuticals

46. Semagla Linux Laboratories

47. Semglyn Zydus Healthcare

48. Semglide Medicamen Life Sc.

49. Semaclu Heet Healthcare

50. Diagluton Dr. Reddys Laboratories

51. Obesema Alkem Laboratories

52. Glp S Alkem Laboratories

53. Glp 1 Neo Ethecom Biosciences

54. Mesemra Alkem Laboratories

55. Semalix Torrent Pharmaceuticals

What Comes Next: Price Wars and Access Expansion

Once generics launch, price erosion is expected to be steep — possibly up to 50–80% below current branded costs — making semaglutide therapies far more affordable for both obesity and diabetes patients.

Industry watchers anticipate that market dynamics will shift from premium mono-brand dominance to fragmented “branded generics wars,” where multiple manufacturers seek share through pricing, pen delivery innovations, and distribution networks, thereby democratizing access, reports TOI.

While cheaper generics could dramatically expand patient access, clinicians warn about appropriate use and medical supervision, especially given widespread interest (and some off-label demand) for obesity indications. Regulatory oversight and physician guidance remain critical.